Almost all PV patients harbor the JAK2 mutation (mostly the V617F mutation in exon 14 and, more rarely, deletions/insertion in exon 12), while approximately 60% of PMF and ET subjects carry the JAK2V617F mutation5,6. The gene discussed is JAK2; the disease is essential thrombocythemia.